TCR2 Therapeutics Inc. (TCRR) News
Filter TCRR News Items
TCRR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest TCRR News From Around the Web
Below are the latest news stories about TCR2 THERAPEUTICS INC that investors may wish to consider to help them evaluate TCRR as an investment opportunity.
TCR² Therapeutics: Betting On A Solid ReversalThesisTCR² Therapeutics (TCRR) develops oncology drug candidates. The company's stock started selling off around last year's September timeframe, leaving TCR² with a 52-week high of $19,03 and a 52-week low of $2,06. The company trades well below cash value at this point. It has a market cap around $140 million, and had $206 million cash in hand at the end of Q2 2022. Whereas earlier reporting by the company had been perceived as very positive by the market, the sell-off starting in September 2021 may have been caused by a perceived efficacy discrepancy in success between malignant pleural/peritonea... |